EGFR and metastatic malignant neoplasm in the lymph nodes: However, our survival analysis results identified only N stage among the clinicopathological factors as a risk factor for predicting PFS in patients receiving EGFR-TKI treatment, while lymph node metastasis is a well-established prognostic feature for predicting the prognosis of NSCLC (39–42).